Controversies in the Management of Lung Cancer: Comorbidities

Catalog

VIKTOR

Podcast | English | 2026 | 48 Min

Create Account

Cost

$0.00

Credit

No Credit Offered

In this episode of Lung Cancer Considered, host Dr. Narjust Florez explores controversies in managing lung cancer patients with comorbidities – those often underrepresented in clinical trials – with Dr. Hina Khan and Dr. Corey Langer, live from the Targeted Therapies of Lung Cancer (TTLC) 2026 conference. The discussion examines treatment decision-making in patients with ECOG performance status 2, renal dysfunction, advanced age, and complex comorbid conditions, emphasizing careful phenotyping, geriatric assessment, and individualized risk–benefit evaluation. The episode also highlights the balance between efficacy, toxicity, quality of life, and patient goals when treating the patients most commonly seen in clinical practice.

Podcast Hosts:

Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA

Podcast Guests:

Hina Khan, MD, Assistant Professor of Medicine, Warren Alpert School of Medicine, Brown University, Providence, RI, USA
Corey Langer, MD, FACP, Director of Thoracic Oncology, Abramson Cancer Center; Professor of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA